Based on our findings suggesting that DARPP-32 increases ERBB3 phosphorylation to bypass gefitinib-induced EGFR inhibition, we next sought to understand whether DARPP-32 drives NSCLC resistance to EGFR TKIs in vivo. Here, ERBB3 is linked to non-small cell lung carcinoma.